List of Digital Health/Medicine Companies in United States - 64

Accel Diagnostics is medical diagnostic company developing proprietary point-of-care diagnostic assay for the diagnosis, monitoring and management of a wide variety of medical conditions. We are dedicated to making a difference in the quality of life of millions of patients through technology and innovation. AccelDx’s technology enables patients and healthcare providers to perform lab-quality medical diagnostic tests anytime and anywhere. The Company's patented platform technology transforms the patient blood testing paradigm, from lab-centered to near-patient. The technology bringing significant advantages in terms of simplicity, time to result, care delivery, and cost over current standard lab-based diagnostics. During COVID-19 pademic Accel Diagnostics began to operate the ADX Diagnostic Lab to provide high quality COVID testing in Houston, TX.

ALR Technologies is a medical device company providing remote monitoring and care facilitation for patients with diabetes. ALRT has developed the FDA-cleared Health-e-Connect System which uploads the data from blood glucose meters onto a secure website where clinicians and Diabetes Care Facilitators can better monitor and coordinate the care of diabetes patients. ALRT's system goal is to assist patients to adhere to their care plan, improving the quality of diabetes care and making such care more cost effective to providers

Aluna is designed to help you understand your chronic respiratory condition (such as asthma) and allow you to take control of your lung health. Using a combination of machine learning, our spirometer device and mobile app, you can now use the daily measurements to help you understand and manage your asthma.

Artera is a SaaS digital health leader redefining patient communications. Artera is trusted by 700+ healthcare systems and federal agencies to facilitate approximately 2.2 billion messages annually, reaching 100+ million patients. The Artera platform integrates across a healthcare organization’s tech stack, EHRs and third-party vendors to unify, simplify and orchestrate digital communications into the patient’s preferred channel (texting, email, IVR, and webchat), in 109+ languages. The Artera impact: more efficient staff, more profitable organizations and a more harmonious patient experience. Founded in 2015, Artera is based in Santa Barbara, California and has been named a Deloitte Technology Fast 500 company (2021, 2022, 2023), and ranked on the Inc. 5000 list of fastest-growing private companies for four consecutive years. Artera is a two-time Best in KLAS winner in Patient Outreach.

Ascertain, a healthcare technology company empowering care teams with AI, helps health systems, payers, and independent provider groups streamline operations and reduce administrative burden. Customers can either deploy Ascertain Automate, an enterprise software platform that uses agentic AI to automate high-volume administrative workflows, or engage Ascertain's tech-enabled services, outsourcing entire workflows to Ascertain's team, which operates the software on their behalf. From prior authorization and eligibility checks to discharge planning and patient scheduling, Ascertain's AI agents navigate complex systems, interpret unstructured data, and integrate across fragmented platforms — enabling faster throughput, lower costs, and more time for patient care. Ascertain was launched by Northwell Holdings, the for-profit investment arm of Northwell Health, and Aegis Ventures.

Astellas Pharma US, Inc. is an affiliate of Tokyo-based Astellas Pharma Inc., a top 20 global pharmaceutical research company. Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the Americas and around the world. All content developed by Astellas Pharma US, Inc. and intended for U.S. audiences.

Auxilium Health is developing low-cost and smart biomaterials for hard-to-heal wounds. Our mission is to empower patients to take control of their healing journey by providing technology that actively heals and monitors wound infections, enabling faster recovery times and better quality of life for patients. We are providing a smarter way to heal wounds, one patient at a time.

Beaufort is a global CRO built around one purpose — helping life science companies improve and save lives through the rapid development and commercialization of innovative products. Our shared interest and commitment to your success drives our entire organization to deliver best-in-class clinical trial services, regulatory strategy and planning, data and business analytics, data management and statistics, and quality services. We are: ◈ MedTech Focused - Industry-leading expertise to streamline your clinical development. ◈ IVD Specialists - Two decades of extensive diagnostic experience. ◈ Results Oriented - Guided by efficient and adaptive clinical trial management. ◈ Partnership Driven - 94% of clients rate Beaufort higher than other CROs Our experience includes: ◈ 500+ Regulatory Submissions including 510(k)s, PMAs, IDEs and CE-Marks ◈ 4,000+ Clinical Study Sites Around the Globe ◈ 1,000+ Clinical Trials Across a Wide Variety of Indications and Testing Platforms ◈ 2,600+ Clinical Professionals in Over 50 Countries See how Beaufort CRO can accelerate your medical innovation -- and put our experience to work for you.

For more than four decades, BioReference has built a legacy based on scientific excellence, innovation and world-class service in laboratory testing solutions. Amidst a tidal wave of change in healthcare in recent years, BioReference has evolved, adding significant services and solutions aimed at addressing the needs of today’s customers. Laboratory testing remains the cornerstone to the services we provide. As we challenge the limits of specialty diagnostics, we are making strategic investments to continue drive innovation and cultivate a unique customer experience, as well as expanding our reach to match the dynamic needs of an ever-changing healthcare system. BioReference offers scientific expertise and laboratory innovation in oncology, urology, and women’s health. Our organization provides credible and tailored solutions for a wide spectrum of customers and patients, including medical practices small and large, hospitals and health systems, correctional institutions, government agencies, educational systems, sport leagues, travel and leisure industries, and retail markets. In addition to an extensive test menu with 99% of tests performed in-house, BioReference’s differentiated offerings include large-scale health screening programs, on-demand mobile phlebotomy, and transformative business solutions that optimize laboratory testing and management. BioReference is part of OPKO Health, Inc., a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets. Headquartered in Elmwood Park, New Jersey, BioReference operates 10 laboratory facilities around the country, is in-network with the largest health plans in the United States, and serves over 19 million patients annually.

Biotricity is a global frontrunner in the realm of digital health. Our mission is to bridge the gap between patients and healthcare providers, ushering in a new era of care delivery that is both efficient and patient-centric. At Biotricity, we're not just transforming remote patient monitoring; we're redefining the very essence of healthcare itself. We are proud to offer award-winning health technology seamlessly integrated with state-of-the-art software. With over 100,000 patients placing their trust in us to improve their long-term cardiac health, we have solidified our position as a trusted healthcare partner. Biotricity's remote patient monitoring devices are designed to optimize patient and healthcare provider workflows. Our goal is to provide critical insights into a patient's health swiftly, resulting in faster treatment and improved outcomes. Our advanced hardware and software solutions enable accurate identification of cardiac problems as they occur, transforming the landscape of care for clinics and patients alike. Physicians can now access real-time data with reports in days, not weeks, while patients wear user-friendly, discreet monitoring devices, offering peace of mind throughout the process. At Biotricity, we firmly believe that the future of healthcare lies in connected medical devices that generate data leveraged by both physicians and individuals. We envision a healthcare ecosystem where these devices seamlessly integrate with big data, predictive AI, and machine intelligence, ushering in an era of better and faster analytics for superior care delivery. Join us as we continue to lead the way in digital health innovation, pioneering advancements that are not just transforming healthcare but also enhancing lives. Together, we are creating a healthier and more connected future. Biotricity's stock is trading under the ticker, “BTCY”.

Cadence Neuroscience is developing a fundamentally new approach to neuromodulation, starting with a therapy to treate severe epilepsy.

CareDx: Transforming Transplant Patient Care Through Novel Surveillance Management Solutions CareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx is at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions. NASDAQ:CDNA About AlloSure® AlloSure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. AlloSure is a clinical-grade, proprietary Next-Generation Sequencing (NGS) based test to detect donor-derived cell-free DNA (dd-cfDNA) in order to identify organ injury in kidney transplant recipients. AlloSure is analytically validated as a sensitive, specific, and precise measurement of dd-cfDNA. AlloSure detects active rejection (acute active ABMR, chronic active ABMR, or TCMR) with high accuracy, outperforms serum creatinine in kidney transplant recipients, and is highly sensitive in distinguishing ABMR from no ABMR. AlloSure is performed in the CareDx CLIA-certified laboratory. http://www.allosure.com/ About AlloMap® AlloMap Molecular Expression Testing is a non-invasive blood test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment. AlloMap testing measures the expression levels of 20 genes from a blood sample. The combined expression of these genes is represented as an AlloMap test score. AlloMap is performed in the CareDx CLIA-certified laboratory and has been commercially available in the United States since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008 and was CE marked for the European Union in 2011. Use of AlloMap is also included in the International Society for Heart and Lung Transplantation (ISHLT) Practice Guidelines, published in August 2010, the worldwide standard for the care of heart transplant patients. http://www.allomap.com/

CrystalGenomics is a commercial stage biopharmaceutical company that is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of infectious disease, oncology, and inflammatory diseases. The Company is headquartered in Korea and has a US presence for global development in California, and it is publicly traded on the KOSDAQ exchange (083790). CrystalGenomics has a product on the market and is developing several novel drug candidates in different therapeutic areas. The marketed product is Acelex® (polmacoxib), a next generation NSAID for the treatment of signs and symptoms of osteoarthritis. The first clinical stage program is CG-745, an epigenetic agent applicable to various types of solid and liquid tumors and currently, phase 2 clinical trials are ongoing for pancreatic cancer and MDS. The second clinical stage program is CG-549, a novel class antibiotic for MRSA where its phase 2a skin infection study in the US had been completed with a positive outcome of 100% clinical cure rate. The Company's therapeutic candidates are discovered and developed through its proprietary discovery platform technology which utilizes the integrated technologies of the SPS™ (technology for structure determination), the SCP™ (technology for the generation of lead compounds) and the SDF™(technology used for lead optimization) technologies. By leveraging its capabilities and the know-how in novel drug discovery and development, CrystalGenomics will continue to strive in making significant contributions for improving human health. For more information, please visit: www.cgxinc.com or www.crystalgenomics.com.

Click Therapeutics, Inc., develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. As a leading innovator of Digital Therapeutics™, we deliver accessible, clinically proven, FDA-regulated prescription treatments to the smartphone in your hand. Our treatments are defined by our commitment to applying technical and scientific rigor and patient-centric design to the development process. This results in uniquely engaging experiences that achieve compelling clinical outcomes for patients seeking new treatment options. We are continuously expanding and refining our shared platform technologies with novel cognitive, behavioral and neuromodulatory mechanisms of action and advanced data-driven tools such as artificial intelligence and machine learning. Digital therapeutics under development on our platform address diverse areas of therapeutic need, including indications in psychiatry, neurology, oncology, cardiology and immunology. Consistently named a best place to work, we foster an inclusive, diverse workforce of innovators, clinicians, scientists, researchers, designers, technologists, engineers and more, united in our mission to provide patients everywhere access to safe and effective prescription digital therapeutics. NOTE: Fake job advertisements and offers are increasingly appearing on the internet. If you have encountered a job posting or have been approached with a job offer that you suspect may be fraudulent, we strongly recommend you do not respond and report it to the Federal Trade Commission and to recruitment@clicktherapeutics.com. Other than your email address or telephone number, which you may provide via a job application portal, Click Therapeutics will never ask you to provide personally identifiable information about yourself (such as a Social Security Number or Driver’s License Number) via a messaging application.

Curavit, the "First All-Virtual CRO", designs and executes decentralized - or "virtual" - clinical trials. Curavit leverages emerging technologies in digital health, cloud computing, and data science to recruit, engage, and monitor diverse patient populations from wherever they live, work, or study; eliminating the need for physical infrastructure and travel, while increasing data quality. Curavit brings together the world's leading researchers, enrolls previously untapped and underserved patient populations, applies machine learning algorithms to health and social engagement information to recruit participants, and leverages leading telehealth, patient data, and medical device technologies. Curavit's central virtual site supports remote monitoring and is always audit ready.

DayTwo is leading the charge in personalized nutrition through cutting-edge microbiome analysis. Our mission is to empower individuals to take control of their health by understanding and optimizing their unique gut microbiome. About Us: We specialize in precision health through microbiome-based insights that drive personalized dietary recommendations. We decode the intricacies of the microbiome and translate it into practical solutions. Services: -Microbiome analysis for personalized nutrition optimization. -Predictive dietary recommendations based on individual microbiome composition. Why Choose Us: -Advanced technology: State-of-the-art sequencing methods (full shotgun) and proprietary algorithms -Supported by science: Microbiome insights combined with 25 years of diverse patient data, bolstered by research published in prestigious journals such as Nature, Cell, JAMA, and Diabetes Care -Largest collection of data: World's largest high-resolution sequenced data set of over 90,000 samples -Personalized approach: Recommendations based on each unique microbiome profile Join us on the journey to better health and unlock the potential of your microbiome with DayTwo. Connect with us to learn more!

We are the first gut microbiome, genetics-based virtual care platform for people struggling with polychronic mental & physical illness associated with weight and gut. We use AI to harness clinical, genetic, gut microbiome, food and behavioral signals to target the root cause of illness. We deliver tailored whole-person care, including remote monitoring, food-as-medicine, pharma reduction, behavioral coaching support, and care coordination. We use AI to harness food information, clinical, genetic, gut microbiome, and behavioral signals, to deliver tailored holistic care, including food as medicine, behavioral coaching support, remote monitoring, and care coordination, to target the root cause of illness. Our customers love us because we acknowledge their unique physiology, lifestyle, food habits and deliver data-driven personalized care supported by specialist coaches that puts the customer in charge.

Develop artificial intelligence that is utilized to aid and augment certified genetic counselors and pharmacists, during pre-test, post-test and support services.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin’s lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Epitel is a digital health company modernizing brain health solutions to improve seizure monitoring and detection.

Essenlix Corporation is a fast-growing startup company in Princeton that develops a new easy-to-use, ultrasensitive, fast, assay platform for life science, diagnostics, and personal health.

ICON works to accelerate the development of live-saving drugs and devices by providing a wide range of consulting, development, and commercialization services.

Imperative Care is a Silicon Valley-based medical technology company researching and developing connected innovations to elevate care for people affected by devastating vascular diseases such as stroke and pulmonary embolism. The company has four businesses focused on addressing specific gaps in treatment and care to make an impact across the entire patient journey. Follow Imperative Care Stroke, Imperative Care Vascular, Telos Health and Kandu Health for product and business-level updates.

Jeeva Clinical Trials Inc. specializes in decentralized clinical trial solutions, offering a unified SaaS platform that enhances global patient engagement and streamlines trial operations. The company utilizes AI-powered tools and modular technology to support efficient trial management, allowing sponsors and medical centers to conduct studies under a single login. Their services include decentralized and hybrid trial solutions, patient recruitment and retention tools, and comprehensive clinical data management. Jeeva's platform features a next-generation Clinical Trial Management System (CTMS) for real-time oversight and protocol adjustments. The company prioritizes security and compliance, adhering to HIPAA, GDPR, and other regulatory standards. Jeeva has successfully implemented its solutions in oncology trials, achieving significant improvements in patient enrollment and data accuracy. They also support academic research, reducing costs and administrative burdens for campus-based studies. With a focus on scalability and workflow standardization, Jeeva provides a patient-centric approach to modern clinical trials.

Karuna Labs, founded in 2016 and based in San Francisco, California, is a digital therapeutics company focused on non-invasive solutions for chronic pain management. The company has secured $3 million in funding from investors such as Anorak Ventures, Baseline Ventures, and DreamIt Ventures. Karuna Labs offers **KarunaHOME**, a 12-week at-home program that combines proprietary neurotechnology with personalized behavioral coaching. The program features the **Karuna Virtual Embodiment Training™ (KVET™)** system, which uses virtual reality technology to provide visual feedback during rehabilitation. Patients receive one-on-one support from trained pain coaches, focusing on sensory reprocessing and cognitive behavioral therapy to help retrain neural pathways associated with chronic pain. The program is designed to be non-pharmacological, flexible, and evidence-based, addressing conditions like low back pain, shoulder pain, and neuropathic pain. Karuna Labs also partners with healthcare providers to integrate its program into clinical workflows, enhancing functional rehabilitation and return-to-work outcomes.

At Kestra, we stand for patients at-risk and the people who care for them. Together we work to protect, support, and empower them with wearable technologies, tools, and better answers as they navigate life's most challenging medical events. Cardiovascular disease is the number one cause of death globally. We're taking a fresh approach to cardiac monitoring and delivery of definitive therapy with wearable products and applications. We aim to make the entire recovery process easier for patients by bringing comfort and assurance to them—along with advanced clinical insights and tools to their medical care teams. Kestra is a privately held, Bain Capital portfolio company, headquartered in Kirkland, Washington USA. Visit us at www.kestramedical.com

Koneksa is a leading patient-centric digital biomarker company for the pharmaceutical and biotechnology industries that develops end-to-end solutions for remotely collected clinical data. Koneksa supports agile decision-making in drug development and market strategy. By delivering integrated solutions for efficient trial designs that produce more meaningful data, Koneksa aims to revolutionize effect detection in clinical research.

We're developing digital treatments for people living with chronic health conditions.

MindMed is a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.

Molecular Testing Labs is a mission-driven, innovative health sciences company specializing in precision laboratory diagnostics. Molecular is committed to revolutionizing accessibility to testing via proprietary technology systems, advanced logistics, and cutting-edge research and development. We are pioneering and innovating distinctive distribution and specimen collection methods that open access to medical testing where geographic, financial, and stigma barriers once created gaps in the healthcare industry. We provide accessible and innovative laboratory solutions through collaborative partnerships with payors, private healthcare institutions, universities, commercial partners, and public health organizations. Molecular Testing Labs is a CLIA-certified and CAP-accredited, state-of-the-art, esoteric and reference laboratory. We specialize in high-complexity, molecular testing with an extensive portfolio of services including infectious disease, toxicology, targeted sequencing, single nucleotide polymorphism (SNP) genotyping, and Next-Generation Sequencing (NGS), and high-resolution immune profiling. Molecular Testing Labs offers a variety of clinical trial services comprising of assay development, trial site training, investigator support, and customized reporting. We apply the maximum level of control to obtain the most consistent and highest quality results. Molecular Testing Labs is founded on three guiding principles – Compliance, Innovation and Partnership. For more information, please visit our corporate website – www.moleculartestinglabs.com.

MCRA is the leading global full-service medical device, diagnostics, and biologics CRO and consulting advisory firm. MCRA delivers to its client's industry experience, integrating its seven business value creators: regulatory, clinical research, reimbursement, healthcare compliance, quality assurance, due diligence and distribution logistics to provide a dynamic, market-leading effort from innovation conception to commercialization. MCRA's integrated application of these key value-creating initiatives provides unparalleled value for its clients. MCRA has offices in Washington, DC, Hartford, CT, New York, NY, London, England, Winterthur, Switzerland, Eschborn, Germany and Tokyo, Japan and serves nearly 1,000 clients globally. Its core focus areas of therapeutic experience include orthopedics, spine, biologics, cardiovascular, diagnostic imaging, wound care, artificial intelligence, dental, anesthesia, general surgery, digital health, neurology, robotics, oncology, general and plastic surgery, urology, and in vitro diagnostic (IVD) devices and medical device cybersecurity. MCRA places particular emphasis on its expertise working with companies in all stages of development and throughout the technology life cycle by ushering technologies from the conceptual pre-clinical stage to market approval.

While our healthcare system has increasingly embraced virtual health in many areas to accelerate access to care, in-person care for patients with cognitive conditions remains the status quo - but Neuroglee Health is making virtual cognitive care a reality. We partner with medical groups to serve as your practice's virtual cognitive care extension – enabling you to provide immediate access to evidence-based care for patients with cognitive disorders and highly coordinated, guided support for the caregivers they rely on. Through our virtual care model, which we developed in collaboration with Mayo Clinic, Neuroglee Health is leaning in to disrupt the status quo. Our partners gain timely access to our team of expert multidisciplinary specialists and powerful, award-winning digital tools: a patient app, care partner app, and clinician dashboard, which optimize patient and caregiver engagement, deliver actionable data-driven insights, and enable coordination across the patient's extended care team. When combined, Neuroglee Health helps patients improve cognition, enhance quality of life, and prolong patient independence, while reducing provider and caregiver burnout. We are on a mission to improve the lives of individuals with cognitive conditions and their loved ones. Join us at www.neuroglee.com.

NFANT Labs is an emerging digital health company focused on improving the outcomes and lives of Neonatal infants. The nfant® Feeding Solution is the first FDA cleared IoT medical device focused on the NICU. We are determined to guide infants to faster and safer feeding.

Octave® Bioscience Inc. is a commercial stage precision-medicine company delivering a new paradigm of care for Multiple Sclerosis and other neurodegenerative diseases. Octave’s Precision Care Solution is the industry’s first set of measurement tools that accurately and objectively measure disease activity, progression, and severity, allowing for better management of complex and high-cost neurodegenerative diseases, starting with Multiple Sclerosis and expanding into Parkinson’s disease. The Octave Solution includes the Octave MSDA Test, the first and only multivariate blood test for Multiple Sclerosis, that measures disease activity, enhanced MRI analytics and protocols, and a clinical care program that tracks and connects patients with MS certified nurse care partners in real time. By combining and analyzing multiple biological and contextual layers of data, delivering longitudinal and holistic perspectives of each patient, and revealing insights at population levels, the Octave Solution addresses unmet needs across the entire ecosystem of care, from patients and providers to pharma and payers. Octave is currently collaborating with leading clinics, payers, and pharma companies across the country.

Onc.AI is venture-capital backed company committed to developing robust, clinically validated, imaging-AI powered clinical management solutions focused on immunotherapy optimization. Using patented, radiomic-based AI models, Onc.AI has developed a clinical decision support platform using routine diagnostic imaging scans specifically for planning and guidance of first-line immune checkpoint inhibitors (ICI) treatment plans.

One Drop is a precision health company combining continuous diagnostics, predictive analytics and machine learning in an award-winning digital solution to deliver cost-saving outcomes for people living with diabetes and other chronic conditions. The goal: empower everyone to take proactive action for better health, peak performance, and more fulfilling lives.

OptraHEALTH® is at the forefront of healthcare innovation, leveraging cutting-edge Artificial Intelligence to transform patient care and streamline operations for providers and payors alike. At the heart of this revolution is our flagship AI platform, HealthFAX™. HealthFAX™ isn't just another healthcare tool—it's a comprehensive AI ecosystem designed to redefine the entire patient journey. From the moment a patient considers seeking care to long after their visit, HealthFAX™ is there, invisibly orchestrating a seamless, efficient, and patient-centric experience. Imagine a healthcare world where: * Digital front doors welcome patients with personalized, AI-driven guidance * Intake processes are streamlined, reducing wait times and frustration * Intelligent triage ensures patients receive the right care at the right time * Accurate cost estimates eliminate billing surprises * AI-powered patient counseling provides round-the-clock support * Insurance information is clarified with ease, reducing administrative burdens But HealthFAX™ doesn't stop there. Post-visit, our AI continues to work tirelessly: * Automating report analysis for faster, more accurate diagnoses * Managing follow-ups to ensure no patient falls through the cracks * Providing actionable insights to continuously improve care quality In the age of value-based care and the No Surprises Act, HealthFAX™ is more than a technological advancement—it's a strategic imperative. By automating complex processes, ensuring regulatory compliance, and enhancing communication at every touchpoint, HealthFAX™ allows healthcare organizations to focus on what truly matters: delivering exceptional patient care. Join the AI-driven healthcare revolution with OptraHEALTH®. Together, we're not just improving healthcare—we're reimagining it.

The Oregon Bioscience Incubator (OBI), formerly known as the Oregon Translational Research and Development Institute (OTRADI), is a 501(c)(3) non-profit research and economic development institute whose mission is to accelerate bioscience industry growth and job creation for the state of Oregon. OBI is committed to economic development, startup business incubation, and broad-based scientific and entrepreneurial mentoring, with the goal of spurring development and translation of innovative research into products and companies that benefit human health. In 2013, OBI opened Oregon's first and only bioscience-focused business incubator--the OTRADI Bioscience Incubator. Since opening, the Oregon Bioscience Incubator has grown from six to twenty-nine startup companies.

Orthogonal is a product development and consulting firm that creates software for medical hardware such as smartphone apps talking to devices that operate directly on the human body to treat sickness and injury. Our solutions take on some of the toughest healthcare problems facing our loved ones, healthcare system, and society. Working at Orthogonal, you will immediately be exposed to projects designed to: •Revolutionize the rapid detection of COVID-19 and other infectious diseases. •Improve the minute-by-minute lives of millions of people suffering from the lifetime affliction of diabetes by managing the delivery of insulin. •Transform the early diagnosis of Alzheimer's disease. •Give patients an at-home means to stimulate specific nerves to treat chronic conditions that drag down their quality of everyday life. •Power the next generation of omics-based cancer-detection systems. Specifically, Orthogonal develops Software as a Medical Device (SaMD), digital therapeutics (DTx), and other types of connected medical devices. We accelerate the product innovation pipeline at medical device, diagnostics, and pharmaceutical manufacturers to modernize patient care and gain competitive advantage. Orthogonal's industry-leading experience with SaMD enables us to rapidly develop, launch, and continuously improve connected, compliant products – and we offer this innovative approach to clients, so they can build their own SaMD product development workflows. Over the last decade, we've worked with partners ranging from startups to Fortune 500 firms to develop and bring their connected devices to market in a highly regulated space.

Oshi Health is the first and only virtual GI center of excellence - setting a new standard for life-changing digestive healthcare - delivering proven care models adapted to scale to help members lasting symptom control and drive savings through reduced avoidable medical spend. As an in-network provider through the nation’s leading health plans, Oshi provides total GI care - covering the full spectrum of GI symptoms and conditions from diagnosis to treatment through a multidisciplinary team of GI specialists, including dietary and behavioral health support.

Patient Sortal is a blockchain-based healthcare data management system for patients with ongoing medical conditions such as chronic diseases or disabilities.

PAVmed (NASDAQ: PAVM) is a highly-differentiated, multi-product medical device company employing a unique and proven business model designed to advance products from concept to commercialization much more rapidly and with significantly less capital than the typical medical device company. This model enables us to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation.

PharmStars is the first and only pharma-focused accelerator for digital health startups, dedicated to driving digital health adoption to improve patient outcomes. We educate and mentor digital health startups seeking engagement with pharma and biotech firms. We are supported by our pharma members who are committed to working with startups that graduate from our accelerator. Through our extensive expertise across pharma, startups, digital health, and innovation, we understand the challenges that pharma and startups face when seeking to collaborate. Our PharmaU program supports digital health startups and our pharma members in “bridging the gap,” leading to greater success and faster adoption of “beyond the molecule” solutions for patients.

Premier Research, a global clinical research, product development, and consulting company, is dedicated to helping innovators transform life-changing ideas and breakthrough science into new medical treatments. We offer strategic solutions across the entire development lifecycle, from pre-clinical through commercialization, specializing in smart study design and full-service clinical trial management. Leveraging technology and therapeutic expertise, we deliver clean, conclusive data with a focus on reducing development timelines, securing access to the right patients, and effectively navigating global regulations to ensure submission-ready results. As an organization that puts patients first, we pride ourselves on helping customers answer the unmet needs of patients across a broad range of medical conditions. Are you ready to make a real difference and help us transform this exciting industry? Follow our company page for more information about us and the work we do, and check out our current openings for your next career move!

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both US FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

Remepy is Pioneering Hybrid Drugs™. Many medical conditions are better treated by combining pharmaceutical and non-pharmaceutical treatments. Hybrid drugs are a new type of drug asset, that combines traditional drugs with proprietary treatment protocols delivered measured and adapted using our AI capabilities. Remepy’s Digital Molecules™ are designed to be the software apps within Hybrid Drugs™. They are based on digital interventions and treatment protocols that are tailored to each medical condition and its corresponding drug and are constantly measured and tracked and personalized using advanced AI capabilities. The Digital Molecules™ enhance brain functions that balance the patient's neuro-endocrine and neuro-immunological systems and boost brain neuroplasticity, in order to optimize drug performance. We also address physical, motor, psychological, and behavioral symptoms Remepy partners with pharma companies to bring Hybrid Drugs™ to market that will combine Remepy’s Digital Molecule™ and traditional drug components.

Sage Bionetworks is a trusted nonprofit leader in data sharing and reuse, enabling a rapid acceleration in biomedical discoveries and the transformation of medicine. Our mission is to drive a new age of discovery through truly open science and radical collaboration. Better Science Together.

SCARLETRED is the worldwide leader in standardized skin imaging and AI powered objective skin analysis. We develop and deliver cutting edge software products and services to biopharma-, biotech- , cosmetics companies, clinical research organisations and health care experts. Our certified, ICH-GCP and EU-GDPR compliant mobile medical device software Scarletred® Vision is the first digital solution solving the problem of lacking standardization and subjective visual skin assessment in pre-clinical, clinical, and post-marketing studies. The highly scalable software platform works infrastructure as well as location independent and enables on-site and home-based monitoring of dermatologic disease as well as digital analysis of skin drug related effects. It it easy to use and reduces development time and opportunity cost in clinical RnD projects. Our digital Products and Services are delivered worldwide from our offices in Europe and USA via flexible Software as a Service (SaaS) agreements.

Servier is a privately held international pharmaceutical company headquartered in France with a passion for innovation that has improved patients' lives around the world. With $4.7 billion in annual sales Servier operates in almost 150 countries worldwide across five therapeutic categories including oncology, cardiovascular, immuno-inflammatory, neuroscience and diabetes. Servier is founded on the principle of serving and governed by an independent non-profit foundation. With this unique operating model, the company can be deliberate about putting patients ahead of profits. In fact, Servier re-invests 25 percent of revenue into research and development each year. Servier is committed to therapeutic progress to serve patient needs and strives to provide future generations with a world where quality healthcare is available and accessible to all. See our community guidelines here: https://www.servier.us/community-guidelines To report a suspected adverse event with a Servier product, please visit: https://www.servier.us/contact-us

Socrates Health Solutions engages in development and marketing of non-invasive blood glucose monitors and value-added integrated software solutions.

Solera Health is committed to changing lives by guiding people to better health solutions. The company has built a dynamic platform that provides intensive, evidence-based, lifestyle and behavioral social interventions to impact the most prevalent and costly chronic conditions in the country. Solera's marketplace strategically matches members to curated networks of digital and community point solutions delivering meaningful health improvements. For payers and employers alike, the Solera Connect platform houses the most innovative health solutions in the industry all while seamlessly handling the most painful tasks involved, including, claims processing, compliance, consumer engagement, eligibility checking, member matching and vendor management.

Sonara® is on a mission to support OTP patients, with a remote dosing solution that makes it easier for people with opioid use disorder to commit to their methadone treatment programs, so they can get their lives back. Our Virtual Dosing Window™ allows patients to record their take-homes by using a phone or computer to scan the QR code on their methadone bottles, and then recording a video of themselves dosing for their care team to review. This patented solution helps build trust between OTP patients and their care teams, empowering clinics with real-time insights to make informed treatment decisions. Sonara also increases patients’ likelihood of earning more take homes, which in turn improves program retention rates. Sonara provides OTPs with the confidence they need to approve more take-home doses responsibly, to improve the quality of life for patients and expand treatment accessibility for those who live farther away from clinics. Notable investors in Sonara include Mark Cuban and First Trust Capital. With Sonara, OTP patients can achieve their treatment goals without putting their lives on hold. To learn more about partnering with Sonara or bringing the Virtual Dosing Window to your OTP, visit sonarahealth.com/contact-us to get in touch.

Sonde Health is a health technology company with a voice-enabled symptom detection and monitoring platform for chronic and mental health conditions. Our products are based on patented and proprietary, best-in-class technology developed by amazing people with advanced audio signal processing, speech science and machine learning backgrounds. We analyze over 4,000 vocal features that reflect changes in your voice caused by the changing physiology of your body due to symptoms of disease. Sonde's platform is designed with people's privacy in mind, and work on most smartphones people already own, preventing you from having to wear something new or add anything to your busy life.

StrokeDx provides portable, rapid, and non-invasive stroke diagnostic and imaging tools.

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at stryker.com and careers.stryker.com. Facts: ● 2023 Sales: $20.5 billion ● Industry: Medical Instruments & Supplies ● Employees: 52,000 worldwide ● 40 years of sales growth leading up to 2020 ● 44+ Manufacturing and R&D Locations Worldwide ● $1.4 billion spent on research and development in 2023 ● ~12,900 patents owned globally in 2023 ● Products sold in ~75 countries ● Fortune 500 Company ● 7 consecutive years as one of Fortune's World's Best Workplaces Stryker’s social media community guidelines: https://www.stryker.com/content/m/legal/social-media-community-guidelines/en/index.html Notice Regarding Employee Conduct on Facebook/LinkedIn Meta/LinkedIn does not permit employers to verify or validate “employees” in the (META: “Works at” LinkedIn: “Experience”) section of users’ profiles. Please be aware that the views expressed by individuals on their personal accounts and do not necessarily represent the views of our company. If you encounter any issues with a person claiming to be our employee, we recommend using the “Report Profile” feature. If you’d like to report concerns to our Ethics Hotline, you may do so at: https://app.convercent.com/en-us/LandingPage/b6bb4e84-9fcb-ea11-a974-000d3ab9f296

Swing Therapeutics was founded in 2019 with the goal of developing digital treatments in disease areas where patients are not well-served, and where digital interventions may be effective. Its focus is on tackling autoimmune conditions and chronic overlapping pain conditions (COPCs) like fibromyalgia where central pain sensitization is a significant factor. The company is investing in research to support the development and validation of its pipeline of prescription-based digital therapies. Swing Therapeutics' near-term goal is to validate its digital program for the treatment of fibromyalgia and bring it to market as an FDA-cleared, prescription-based digital therapeutic.

Texas Tech University Health Sciences Center is a Higher Education institution that focuses on healthcare education and medical research.

The Weinberg Group, a ProPharma Group company, is the global leader in regulatory and compliance services, with headquarters in Washington, D.C. For over 35 years, we have provided biotech, medical device, and pharmaceutical consulting services to companies of every size on every continent, supplying them with viable and efficient drug development pathways and compliance solutions. The Weinberg Group was acquired by ProPharma Group on January 25, 2019. By joining forces, we expand our current service portfolio of pre-approval/pre-clinical regulatory service solutions to also now include post-approval regulatory services, establishing an end-to-end global solution for our clients. Our service footprint now allows us to service clients at all stages of drug, device and biotechnology development, and in any geographic region.

Truveta is a growing collective of health systems in the US with a mission of Saving Lives with Data. Truveta delivers the most complete, clean, and timely regulatory-grade EHR data for scientifically rigorous research. Truveta is trusted by leading life science, government, health system, academic and research organizations to accelerate adoption of new therapies, improve clinical trials, and enhance patient care.

University Hospital is a healthcare facility that provides medical services and health services.

VideaHealth is on mission to transform dentistry through artificial intelligence. Rooted in AI research conducted at Harvard and MIT, VideaHealth’s FDA-cleared dental AI platform is proven to increase diagnostic accuracy, grow treatment plan values, and improve case acceptance rates. With the largest and most diverse data set in the market, VideaHealth is the partner of choice for the nation's leading DSOs - and is trusted by dentists, hygienists and patients. Backed by leading venture capital firms Spark Capital, Zetta Venture Partners and Pillar VC, VideaHealth is headquartered in Boston.

Wavely Diagnostics builds phone-based tools to support pediatric care. Their first tool is a phone app that can detect fluid in the middle ear to help a doctor diagnose and treat ear infections remotely.

Wellinks is the COPD disease management company providing individuals with the personalized care and support necessary for successful self-management. We prioritize the unique needs of each member to establish a clear path to better health. Our programs extend the reach of existing care resources, and fill gaps where they are absent. Respiratory specialists and our health coaches work one-on-one and across a community of members to personalize the experience and unlock the power of the individual in their journey to better health. Our care pathways are supported by a suite of innovative and simple to use technology, including a kit of connected devices and the Wellinks app, bridging the gap between doctor visits and allow patients to manage their COPD from wherever life takes them. Wellinks provides a welcoming and inclusive environment where members trust they will receive the best possible care and guidance in managing their COPD. Our solution is intuitive, engaging, and fully integrated across the care journey — empowering patients with the peace of mind and freedom to live fully and breathe freely.

XP Health is a digital-first vision platform focused on eye exams and eyewear that uses customer-centric design and technology to be more affordable, accessible, and provide a better member experience. XP Health was founded to combat the often confusing, expensive, and frustrating experiences common with vision insurance. The company was named to Fast Company’s list of “The World's Most Innovative Companies,” and in 2022 expanded from 30 to 1500+ customers.